Resistant thrombocytopenia in an HIV and hepatitis C patient: treatment response with novel agent eltrombopag
AbstractHIV-associated thrombocytopenia is a dis- ease which can be recurrent to standard therapy which includes highly active antiretroviral therapy (HAART) therapy, steroids and immunoglobulin. We report a patient with HIV and hepatitis C who presented with resistant thrombocytopenia. Treatment with Eltrombopag – a thrombopoeitin receptor agonist showed initial good response with recurrence of thrombocytopenia. This novel agent could be considered as a treatment option prior to splenectomy and may be useful as a tempo- rizing measure.
Google ScholarGoogle Scholar
- Abstract views: 1703
- PDF: 99
- HTML: 90
Copyright (c) 2011 Rajakrishnan Vijayakrishnan, Sourbha Dani, Aparna Ramasubramanian, Rekha Nair, Tony M. Samaha
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.